Shares of OvaScience, Inc. (OVAS) are higher by 4% to $46.73 in late trading on Friday, following a positive Barron’s article that suggest shares of the fertility specialist could double.
OvaScience stock gapped up at the open Friday, but was range-bound throughout the first-half of the session. It extended afterwards, printing an intraday high of $48.74 with the last hour of trading spent drifting laterally. The stock is currently getting closer to retest its $48.85 1-month high.
Fundamentally, OVAS shows the following financial data:
- $60.23 million in cash in most recent quarter
- $65.57 million t-12 total assets
- $55.33 million total equity
- ($49.52) million annual net income
On valuation measures, Ovascience Inc. shares have a T-12 price/book ratio of 19.59. EPS is ($2.16). The name has a market cap of $1.19 billion and a median Wall Street price target of $57.00 with a high target of $100.00. Currently there are 7 analysts that rate OVAS a ‘Buy’. No analyst rates it a ‘Hold’ or a ‘Sell’.
In terms of share statistics, Ovascience Inc. has a total of 26.58 million shares outstanding with 29.76% held by insiders and 58.10% held by institutions. The stock’s short interest currently stands at 15.75%, bringing the total number of shares sold short to 3.26 million.
Shares of the Cambridge Massachusetts-based company are up a staggering 330.53% year-over-year and 1.74% year-to-date.
OvaScience, Inc. engages in the discovery, development, and commercialization of new treatments for infertility. The company was founded in 2011 and is based in Cambridge, Massachusetts.